Correction to: Evidence-based Korean guidelines for the clinical management of multiple myeloma: addressing 12 key clinical questions (Blood Research, (2025), 60, 1, (9), 10.1007/s44313-025-00055-9)

On page 11, within the recommendations section, the second paragraph incorrectly reads: “MRD assessment should be performed using multicolor flow cytometry, next-generation flow cytometry, or next-generation sequencing with a sensitivity of at least 10 units during clinical evaluation following treatment” but it should have read “MRD assessment should be performed using multicolor flow cytometry, next-generation flow cytometry, or next-generation sequencing with a sensitivity of at least 10^–4 during clinical evaluation following treatment.” The original article has been updated [1].